Literature DB >> 3873401

Divergent expression of HLA-DC/MB, -DR, and -SB region products on normal and pathological tissues as detected by monoclonal antibodies.

C Müller, A Ziegler, C Muller, M Hadam, H D Waller, P Wernet, G Müller.   

Abstract

A group of eight monoclonal antibodies directed against different monomorphic determinants of HLA-class II molecules was used to investigate the distribution of HLA-DC/DS/MB, -DR and -SB-like antigens on normal and pathological lymphoid and nonlymphoid tissues of human adult and fetal donors. HLA-MB/DC/DS-like molecules, as defined by the antibody TU 22, showed the most limited distribution as they were detected on B-lymphocytes, monocyte/macrophage subpopulations and distinct interstitial cells of various organs. HLA-DR and -SB-like antigens characterized by the other anti-HLA-class II reagents (TU34, TU35, TU37, TU39, TU43, TU58) were also present on these cell types. However, selective expression of HLA-DR and/or -SB like molecules was demonstrated with these antibodies on certain vascular endothelia, as well as different B-cell lymphomas and distinct epithelial cells in adults. Exclusive reactivity of the antibody TU39 shown on endothelial cells of fetal liver and kidney suggested specific functions of HLA-SB antigens during ontogeny. Furthermore, HLA-DR and/or -SB like molecules but not TU22+ HLA-DC/MB antigens were found to be inducible on normally Ia-like antigen negative epithelial cells of various diseased organs. Implications of this differential tissue distribution of HLA-DC/MB/DS, -DR and -SB like products in relation to organ transplantation, regulation of immune responses and cell differentiation are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3873401     DOI: 10.1016/s0171-2985(85)80036-x

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  14 in total

1.  Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin's gastric lymphoma patients.

Authors:  Alexander Darom; Ilias P Gomatos; Emmanuel Leandros; Emmu Chatzigianni; Dimitris Panousopoulos; Manousos M Konstadoulakis; George Androulakis
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

2.  HLA-class II antigens on human hematopoietic progenitors.

Authors:  F W Busch; M Langer; G Pawelec; A Ziegler; P Wernet; H J Bühring; P Meyer; C Müller
Journal:  Blut       Date:  1987-03

3.  HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities.

Authors:  M Feinmesser; A Sulkes; S Morgenstern; J Sulkes; S Stern; E Okon
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

4.  MHC class II antigen and immunoglobulin expression in spontaneous phenotypic variants of the Burkitt's lymphoma cell line Namalwa.

Authors:  K Guy; P G Middleton; L J Docherty; C L De Angelis; C M Steel
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

5.  Mature human eosinophils have the capacity to express HLA-DR.

Authors:  D R Lucey; A Nicholson-Weller; P F Weller
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

6.  Differential expression of Ia antigens by rheumatoid synovial lining cells.

Authors:  G R Burmester; B Jahn; P Rohwer; J Zacher; R J Winchester; J R Kalden
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

7.  Genetic and serological heterogeneity of the supertypic HLA-B locus specificities Bw4 and Bw6.

Authors:  C A Müller; G Engler-Blum; V Gekeler; I Steiert; E Weiss; H Schmidt
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

8.  Adhesion molecules on CD34+ hematopoietic cells in normal human bone marrow and leukemia.

Authors:  M A Reuss-Borst; H J Bühring; G Klein; C A Müller
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

9.  Impaired antigen-presenting capability of monocytes correlated with their decreased expression of HLA-II antigens in patients with myeloid leukemia.

Authors:  F L Gong; X W Feng; H Grosse-Wilde
Journal:  J Tongji Med Univ       Date:  1993

10.  In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN alpha treatment.

Authors:  C A Müller; J Walz; R Zinser; H J Bühring; B Steinke; H Schmidt
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.